Identification and Validation of a Reliable Prognostic Eleven-Genes Signature for Hepatocellular Carcinoma

Abstract Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality and mortality. Although advances in early diagnosis, disease management and treatment of HCC, the outcomes remain unsatisfactory. This study aimed to identify the reliable prognostic biomarkers based integrated bioinformatics analysis to predict and improve the survival of HCC patients. Methods: The gene expression or transcriptome profiles and survival of HCC were acquired from the Gene Expression Omnibus database (GEO) and the Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) were screened out by the limma or edgeR package in the R software. Univariate, LASSO and multivariate Cox regression analyses were conducted to explore survival-related signature. Subsequently, a prognostic model and nomogram composed of prognostic signature were constructed for assessing overall survival (OS). Kaplan-Meier analysis, receiver operating characteristic (ROC) curve and stratified analysis were performed to confirm the prognostic performance of the prognostic model.Results: Compared with nontumor samples, 451 reliable DEGs were identified using the robust rank aggregation and overlap validation. Eleven survival-related DEGs were selected for the construction of a risk evaluation model, which could efficiently distinguish high-risk patients from low-risk patients and even be feasible in the subgroups of stages and age. Further analyses suggested the positive and independent prognostic performance of the model compared to other clinical characteristics (P< 0.05, ROC > 0.7). Finally, a prognostic nomogram composed of the model was constructed for assessing the overall survival, and Harrell’s concordance index and calibration curves demonstrated its efficient predictive performance. Conclusion: The predictive model and nomogram will contribute directly to further clinical applications in the individualized survival prediction, the improvement of treatment strategies and more accurate management for patients with HCC.

Download Full-text

A Nomogram Based on a Three-Gene Signature Derived from AATF Coexpressed Genes Predicts Overall Survival of Hepatocellular Carcinoma Patients

BioMed Research International ◽

10.1155/2020/7310768 ◽

2020 ◽

Vol 2020 ◽

pp. 1-17

Author(s):

Jun Liu ◽

Jianjun Lu ◽

Zhanzhong Ma ◽

Wenli Li

Keyword(s):

Gene Expression ◽

Hepatocellular Carcinoma ◽

Overall Survival ◽

Clinical Practice ◽

Correlation Coefficient ◽

Cox Regression ◽

Prognostic Significance ◽

Gene Signature ◽

Cancer Genome ◽

Survival Prediction

Background. Hepatocellular carcinoma (HCC) is a common cancer with an extremely high mortality rate. Therefore, there is an urgent need in screening key biomarkers of HCC to predict the prognosis and develop more individual treatments. Recently, AATF is reported to be an important factor contributing to HCC. Methods. We aimed to establish a gene signature to predict overall survival of HCC patients. Firstly, we examined the expression level of AATF in the Gene Expression Omnibus (GEO), the Cancer Genome Atlas (TCGA), and the International Union of Cancer Genome (ICGC) databases. Genes coexpressed with AATF were identified in the TCGA dataset by the Poisson correlation coefficient and used to establish a gene signature for survival prediction. The prognostic significance of this gene signature was then validated in the ICGC dataset and used to build a combined prognostic model for clinical practice. Results. Gene expression data and clinical information of 2521 HCC patients were downloaded from three public databases. AATF expression in HCC tissue was higher than that in matched normal liver tissues. 644 genes coexpressed with AATF were identified by the Poisson correlation coefficient and used to establish a three-gene signature (KIF20A, UCK2, and SLC41A3) by the univariate and multivariate least absolute shrinkage and selection operator Cox regression analyses. This three-gene signature was then used to build a combined nomogram for clinical practice. Conclusion. This integrated nomogram based on the three-gene signature can predict overall survival for HCC patients well. The three-gene signature may be a potential therapeutic target in HCC.

Download Full-text

Tumor microenvironment related novel signature predict lung adenocarcinoma survival

PeerJ ◽

10.7717/peerj.10628 ◽

2021 ◽

Vol 9 ◽

pp. e10628

Author(s):

Juan Chen ◽

Rui Zhou

Keyword(s):

Gene Expression ◽

Overall Survival ◽

Regression Analysis ◽

Tumor Microenvironment ◽

Prognostic Model ◽

Cox Regression ◽

Survival Prediction ◽

Clinical Parameters ◽

Ppi Network ◽

Cox Regression Analysis

Background Lung adenocarcinoma (LUAD) is the most common histological type of lung cancers, which is the primary cause of cancer‐related mortality worldwide. Growing evidence has suggested that tumor microenvironment (TME) plays a pivotal role in tumorigenesis and progression. Hence, we investigate the correlation of TME related genes with LUAD prognosis. Method The information of LUAD gene expression data was obtained from The Cancer Genome Atlas (TCGA). According to their immune/stromal scores calculated by the ESTIMATE algorithm, differentially expressed genes (DEGs) were identified. Then, we performed univariate Cox regression analysis on DEGs to obtain genes that are apparently bound up with LUAD survival (SurGenes). Functional annotation and protein-protein interaction (PPI) was also conducted on SurGenes. By validating the SurGenes with data sets of lung cancer from the Gene Expression Omnibus (GEO), 106 TME related SurGenes were generated. Further, intersection analysis was executed between the 106 TME related SurGenes and hub genes from PPI network, PTPRC and CD19 were obtained. Gene Set Enrichment Analysis and CIBERSORT analysis were performed on PTPRC and CD19. Based on the TCGA LUAD dataset, we conducted factor analysis and Step-wise multivariate Cox regression analysis for 106 TME related SurGenes to construct the prognostic model for LUAD survival prediction. The LUAD dataset in GEO (GSE68465) was used as the testing dataset to confirm the prognostic model. Multivariate Cox regression analysis was used between risk score from the prognostic model and clinical parameters. Result A total of 106 TME related genes were collected in our research totally, which were markedly correlated with the overall survival (OS) of LUAD patient. Bioinformatics analysis suggest them mainly concentrated on immune response, cell adhesion, and extracellular matrix. More importantly, among 106 TME related SurGenes, PTPRC and CD19 were highly interconnected nodes among PPI network and correlated with immune activity, exhibiting significant prognostic potential. The prognostic model was a weighted linear combination of the 106 genes, by which the low-OS LUAD samples could be separated from the high-OS samples with success. This model was also able to rebustly predict the situation of survival (training set: p-value < 0.0001, area under the curve (AUC) = 0.649; testing set: p-value = 0.0009, AUC = 0.617). By combining with clinical parameters, the prognostic model was optimized. The AUC achieved 0.716 for 3 year and 0.699 for 5 year. Conclusion A series of TME-related prognostic genes were acquired in this research, which could reflect immune disorders within TME, and PTPRC and CD19 show the potential to be an indicator for LUAD prognosis and tumor microenvironment modulation. The prognostic model constructed base on those prognostic genes presented a high predictive ability, and may have clinical implications in the overall survival prediction of LUAD.

Download Full-text

A signature of seven immune‐related genes predicts overall survival in male gastric cancer patients

Cancer Cell International ◽

10.1186/s12935-021-01823-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xin Xu ◽

Yida Lu ◽

Youliang Wu ◽

Mingliang Wang ◽

Xiaodong Wang ◽

...

Keyword(s):

Gene Expression ◽

Gastric Cancer ◽

Overall Survival ◽

Risk Score ◽

Cox Regression ◽

External Validation ◽

The Cancer Genome Atlas ◽

Differentially Expressed ◽

Survival Prediction ◽

Immune Related Genes

Abstract Background Gastric cancer (GC) has a high mortality rate and is one of the most fatal malignant tumours. Male sex has been proven as an independent risk factor for GC. This study aimed to identify immune-related genes (IRGs) associated with the prognosis of male GC. Methods RNA sequencing and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed IRGs between male GC and normal tissues were identified by integrated bioinformatics analysis. Univariate and multivariate Cox regression analyses were applied to screen survival-associated IRGs. Then, GC patients were separated into high- and low-risk groups based on the median risk score. Furthermore, a nomogram was constructed based on the TCGA dataset. The prognostic value of the risk signature model was evaluated by Kaplan-Meier curve, receiver operating characteristic (ROC), Harrell’s concordance index and calibration curves. In addition, the gene expression dataset from the Gene Expression Omnibus (GEO) was also downloaded for external validation. The relative proportions of 22 types of infiltrating immune cells in each male GC sample were evaluated using CIBERSORT. Results A total of 276 differentially expressed IRGs were screened, including 189 up-regulated and 87 down-regulated genes. Subsequently, a seven-IRGs signature (LCN12, CCL21, RNASE2, CGB5, NRG4, AGTR1 and NPR3) was identified to be significantly associated with the overall survival (OS) of male GC patients. Survival analysis indicated that patients in the high-risk group exhibited a poor clinical outcome. The results of multivariate analysis revealed that the risk score was an independent prognostic factor. The established nomogram could be used to evaluate the prognosis of individual male GC patients. Further analysis showed that the prognostic model had excellent predictive performance in both TCGA and validated cohorts. Besides, the results of tumour-infiltrating immune cell analysis indicated that the seven-IRGs signature could reflect the status of the tumour immune microenvironment. Conclusions Our study developed a novel seven-IRGs risk signature for individualized survival prediction of male GC patients.

Download Full-text

Prognostic Power of a Chaperonin Containing TCP-1 Subunit Genes Panel for Hepatocellular Carcinoma

Frontiers in Genetics ◽

10.3389/fgene.2021.668871 ◽

2021 ◽

Vol 12 ◽

Author(s):

Wenli Li ◽

Jun Liu ◽

Hetong Zhao

Keyword(s):

Gene Expression ◽

Hepatocellular Carcinoma ◽

Overall Survival ◽

Cox Regression ◽

Gene Signature ◽

Cancer Genome ◽

Medical Decision ◽

Survival Prediction ◽

Cox Regression Analysis ◽

T Complex

Chaperonin containing TCP-1 (T-complex protein 1) (CCT) is a large molecular weight complex that contains nine subunits (TCP1, CCT2, CCT3, CCT4, CCT5, CCT6A, CCT6B, CCT7, CCT8). This study aimed to reveal key genes which encode CCT subunits for prognosis and establish prognostic gene signatures based on CCT subunit genes. The data was downloaded from The Cancer Genome Atlas, International Cancer Genome Consortium and Gene Expression Omnibus. CCT subunit gene expression levels between tumor and normal tissues were compared. Corresponding Kaplan-Meier analysis displayed a distinct separation in the overall survival of CCT subunit genes. Correlation analysis, protein-protein interaction network, Gene Ontology analysis, immune cells infiltration analysis, and transcription factor network were performed. A nomogram was constructed for the prediction of prognosis. Based on multivariate Cox regression analysis and shrinkage and selection method for linear regression model, a three-gene signature comprising CCT4, CCT6A, and CCT6B was constructed in the training set and significantly associated with prognosis as an independent prognostic factor. The prognostic value of the signature was then validated in the validation and testing set. Nomogram including the signature showed some clinical benefit for overall survival prediction. In all, we built a novel three-gene signature and nomogram from CCT subunit genes to predict the prognosis of hepatocellular carcinoma, which may support the medical decision for HCC therapy.

Download Full-text

Identification of an E2F Target‐Related Gene Signature to Improve the Prognosis Prediction for Patients with Hepatocellular Carcinoma

10.21203/rs.3.rs-706781/v1 ◽

2021 ◽

Author(s):

Jing Bian ◽

Xi Chen ◽

Mingyan Jiang ◽

Xinghua Gao

Keyword(s):

Gene Expression ◽

Hepatocellular Carcinoma ◽

Cox Regression ◽

Malignant Tumors ◽

Single Gene ◽

Gene Set Enrichment Analysis ◽

The Cancer Genome Atlas ◽

Survival Prediction ◽

Prognostic Signature ◽

Clinical Patient

Abstract Liver cancer is one of the most common malignant tumors in the world, of which hepatocellular carcinoma (HCC) is the most common histological subtype. Although thousands of biomarkers related to HCC survival and prognosis have been found through database mining, the predictive effects of single-gene biomarkers are not specific enough. Therefore, we aimed to construct a pathway-related signature that could effectively forecast HCC prognosis. We obtained gene expression data and clinical patient information from The Cancer Genome Atlas database (TCGA). Univariate and multivariate Cox regression analyses were used to identify genes enriched in the E2F target gene pathway by Gene Set Enrichment Analysis. In the training set, NBN, PHF5A, CDCA8, AK2, and EXOSC8 were significantly associated with overall survival. They were validated in the test and entire groups, confirmed by Gene Expression Omnibus (GEO), and compared with two known prognostic signatures for HCC. Overall, we demonstrated a novel five-mRNA prognostic signature based on E2F targets that successfully predicted the survival of HCC patients, is independent of clinicopathological data, and displayed superior prediction performance in HCC prognosis. Our study elucidates the cell cycle mechanism in identifying patients with poor HCC prognosis. The application of our five-mRNA prognostic signature may improve risk stratification in HCC patients and existing methods for survival prediction.

Download Full-text

A signature of seven immune-related genes predicts overall survival in male gastric cancer patients

10.21203/rs.3.rs-52209/v2 ◽

2021 ◽

Author(s):

Xin Xu ◽

Yida Lu ◽

Youliang Wu ◽

Mingliang Wang ◽

Xiaodong Wang ◽

...

Keyword(s):

Gene Expression ◽

Gastric Cancer ◽

Overall Survival ◽

Risk Score ◽

Cox Regression ◽

External Validation ◽

The Cancer Genome Atlas ◽

Differentially Expressed ◽

Survival Prediction ◽

Immune Related Genes

Abstract Background: Gastric cancer (GC) has a high mortality rate and is one of the most fatal malignant tumours. Male sex has been proven as an independent risk factor for GC. This study aimed to identify immune-related genes (IRGs) associated with the prognosis of male GC.Method: RNA sequencing and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed IRGs between male GC and normal tissues were identified by integrated bioinformatics analysis. Univariate and multivariate Cox regression analyses were applied to screen survival-associated IRGs. Then, GC patients were separated into high- and low-risk groups based on the median risk score. Furthermore, a nomogram was constructed based on the TCGA dataset. The prognostic value of the risk signature model was evaluated by Kaplan-Meier curve, receiver operating characteristic (ROC), Harrell’s concordance index and calibration curves. In addition, the gene expression dataset from the Gene Expression Omnibus (GEO) was also downloaded for external validation. The relative proportions of 22 types of infiltrating immune cells in each male GC sample were evaluated using CIBERSORT.Results: A total of 276 differentially expressed IRGs were screened, including 189 up-regulated and 87 down-regulated genes. Subsequently, a seven-IRGs signature (LCN12, CCL21, RNASE2, CGB5, NRG4, AGTR1 and NPR3) was identified to be significantly associated with the overall survival (OS) of male GC patients. Survival analysis indicated that patients in the high-risk group exhibited a poor clinical outcome. The results of multivariate analysis revealed that the risk score was an independent prognostic factor. The established nomogram could be used to evaluate the prognosis of individual male GC patients. Further analysis showed that the prognostic model had excellent predictive performance in both TCGA and validated cohorts. Besides, the results of tumour-infiltrating immune cell analysis indicated that the seven-IRGs signature could reflect the status of the tumour immune microenvironment.Conclusions: Our study developed a novel seven-IRGs risk signature for individualized survival prediction of male GC patients.

Download Full-text

Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma

BMC Cancer ◽

10.1186/s12885-021-08314-5 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Dongsheng He ◽

Shengyin Liao ◽

Lifang Cai ◽

Weiming Huang ◽

Xuehua Xie ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Prognostic Factors ◽

Risk Score ◽

Prognostic Model ◽

Cox Regression ◽

The Cancer Genome Atlas ◽

Integrated Analysis ◽

Calibration Plot ◽

Clinical Parameters ◽

T Stage

Abstract Background The potential reversibility of aberrant DNA methylation indicates an opportunity for oncotherapy. This study aimed to integrate methylation-driven genes and pretreatment prognostic factors and then construct a new individual prognostic model in hepatocellular carcinoma (HCC) patients. Methods The gene methylation, gene expression dataset and clinical information of HCC patients were downloaded from The Cancer Genome Atlas (TCGA) database. Methylation-driven genes were screened with a Pearson’s correlation coefficient less than − 0.3 and a P value less than 0.05. Univariable and multivariable Cox regression analyses were performed to construct a risk score model and identify independent prognostic factors from the clinical parameters of HCC patients. The least absolute shrinkage and selection operator (LASSO) technique was used to construct a nomogram that might act to predict an individual’s OS, and then C-index, ROC curve and calibration plot were used to test the practicability. The correlation between clinical parameters and core methylation-driven genes of HCC patients was explored with Student’s t-test. Results In this study, 44 methylation-driven genes were discovered, and three prognostic signatures (LCAT, RPS6KA6, and C5orf58) were screened to construct a prognostic risk model of HCC patients. Five clinical factors, including T stage, risk score, cancer status, surgical method and new tumor events, were identified from 13 clinical parameters as pretreatment-independent prognostic factors. To avoid overfitting, LASSO analysis was used to construct a nomogram that could be used to calculate the OS in HCC patients. The C-index was superior to that from previous studies (0.75 vs 0.717, 0.676). Furthermore, LCAT was found to be correlated with T stage and new tumor events, and RPS6KA6 was found to be correlated with T stage. Conclusion We identified novel therapeutic targets and constructed an individual prognostic model that can be used to guide personalized treatment in HCC patients.

Download Full-text

A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma

BioData Mining ◽

10.1186/s13040-021-00261-y ◽

2021 ◽

Vol 14 (1) ◽

Author(s):

Qian Yan ◽

Wenjiang Zheng ◽

Boqing Wang ◽

Baoqian Ye ◽

Huiyan Luo ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Overall Survival ◽

High Risk ◽

Risk Score ◽

Immune Cells ◽

Prognostic Model ◽

Risk Groups ◽

Low Risk ◽

Prognostic Performance ◽

Immune Related Genes

Abstract Background Hepatocellular carcinoma (HCC) is a disease with a high incidence and a poor prognosis. Growing amounts of evidence have shown that the immune system plays a critical role in the biological processes of HCC such as progression, recurrence, and metastasis, and some have discussed using it as a weapon against a variety of cancers. However, the impact of immune-related genes (IRGs) on the prognosis of HCC remains unclear. Methods Based on The Cancer Gene Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort) datasets, we integrated the ribonucleic acid (RNA) sequencing profiles of 424 HCC patients with IRGs to calculate immune-related differentially expressed genes (DEGs). Survival analysis was used to establish a prognostic model of survival- and immune-related DEGs. Based on genomic and clinicopathological data, we constructed a nomogram to predict the prognosis of HCC patients. Gene set enrichment analysis further clarified the signalling pathways of the high-risk and low-risk groups constructed based on the IRGs in HCC. Next, we evaluated the correlation between the risk score and the infiltration of immune cells, and finally, we validated the prognostic performance of this model in the GSE14520 dataset. Results A total of 100 immune-related DEGs were significantly associated with the clinical outcomes of patients with HCC. We performed univariate and multivariate least absolute shrinkage and selection operator (Lasso) regression analyses on these genes to construct a prognostic model of seven IRGs (Fatty Acid Binding Protein 6 (FABP6), Microtubule-Associated Protein Tau (MAPT), Baculoviral IAP Repeat Containing 5 (BIRC5), Plexin-A1 (PLXNA1), Secreted Phosphoprotein 1 (SPP1), Stanniocalcin 2 (STC2) and Chondroitin Sulfate Proteoglycan 5 (CSPG5)), which showed better prognostic performance than the tumour/node/metastasis (TNM) staging system. Moreover, we constructed a regulatory network related to transcription factors (TFs) that further unravelled the regulatory mechanisms of these genes. According to the median value of the risk score, the entire TCGA cohort was divided into high-risk and low-risk groups, and the low-risk group had a better overall survival (OS) rate. To predict the OS rate of HCC, we established a gene- and clinical factor-related nomogram. The receiver operating characteristic (ROC) curve, concordance index (C-index) and calibration curve showed that this model had moderate accuracy. The correlation analysis between the risk score and the infiltration of six common types of immune cells showed that the model could reflect the state of the immune microenvironment in HCC tumours. Conclusion Our IRG prognostic model was shown to have value in the monitoring, treatment, and prognostic assessment of HCC patients and could be used as a survival prediction tool in the near future.

Download Full-text

Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma

Bioscience Reports ◽

10.1042/bsr20203263 ◽

2020 ◽

Vol 40 (11) ◽

Author(s):

Xiaofei Wang ◽

Jie Qiao ◽

Rongqi Wang

Keyword(s):

Gene Expression ◽

Hepatocellular Carcinoma ◽

Overall Survival ◽

Risk Score ◽

Expression Profiles ◽

Univariate Analysis ◽

Cancer Genome ◽

The Cancer Genome Atlas ◽

Good Prediction ◽

Expression Levels

Abstract The present study aimed to construct a novel signature for indicating the prognostic outcomes of hepatocellular carcinoma (HCC). Gene expression profiles were downloaded from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) databases. The prognosis-related genes with differential expression were identified with weighted gene co-expression network analysis (WGCNA), univariate analysis, the least absolute shrinkage and selection operator (LASSO). With the stepwise regression analysis, a risk score was constructed based on the expression levels of five genes: Risk score = (−0.7736* CCNB2) + (1.0083* DYNC1LI1) + (−0.6755* KIF11) + (0.9588* SPC25) + (1.5237* KIF18A), which can be applied as a signature for predicting the prognosis of HCC patients. The prediction capacity of the risk score for overall survival was validated with both TCGA and ICGC cohorts. The 1-, 3- and 5-year ROC curves were plotted, in which the AUC was 0.842, 0.726 and 0.699 in TCGA cohort and 0.734, 0.691 and 0.700 in ICGC cohort, respectively. Moreover, the expression levels of the five genes were determined in clinical tumor and normal specimens with immunohistochemistry. The novel signature has exhibited good prediction efficacy for the overall survival of HCC patients.

Download Full-text

Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma

Technology in Cancer Research & Treatment ◽

10.1177/15330338211041425 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110414

Author(s):

Xiaoyong Li ◽

Jiaqong Lin ◽

Yuguo pan ◽

Peng Cui ◽

Jintang Xia

Keyword(s):

Hepatocellular Carcinoma ◽

Overall Survival ◽

Regression Analysis ◽

Prognostic Model ◽

Cox Regression ◽

Risk Group ◽

Gene Signature ◽

Regression Analyses ◽

Related Gene ◽

Cox Regression Analysis

Background: Liver progenitor cells (LPCs) play significant roles in the development and progression of hepatocellular carcinoma (HCC). However, no studies on the value of LPC-related genes for evaluating HCC prognosis exist. We developed a gene signature of LPC-related genes for prognostication in HCC. Methods: To identify LPC-related genes, we analyzed mRNA expression arrays from a dataset (GSE57812 & GSE 37071) containing LPCs, mature hepatocytes, and embryonic stem cell samples. HCC RNA-Seq data from The Cancer Genome Atlas (TCGA) were used to explore the differentially expressed genes (DEGs) related to prognosis through DEG analysis and univariate Cox regression analysis. Lasso and multivariate Cox regression analyses were performed to construct the LPC-related gene prognostic model in the TCGA training dataset. This model was validated in the TCGA testing set and an external dataset (International Cancer Genome Consortium [ICGC] dataset). Finally, we investigated the relationship between this prognostic model with tumor-node-metastasis stage, tumor grade, and vascular invasion of HCC. Results: Overall, 1770 genes were identified as LPC-related genes, of which 92 genes were identified as DEGs in HCC tissues compared with normal tissues. Furthermore, we randomly assigned patients from the TCGA dataset to the training and testing cohorts. Twenty-six DEGs correlated with overall survival (OS) in the univariate Cox regression analysis. Lasso and multivariate Cox regression analyses were performed in the TCGA training set, and a 3-gene signature was constructed to stratify patients into 2 risk groups: high-risk and low-risk. Patients in the high-risk group had significantly lower OS than those in the low-risk group. Receiver operating characteristic curve analysis confirmed the signature's predictive capacity. Moreover, the risk score was confirmed to be an independent predictor for patients with HCC. Conclusion: We demonstrated that the LPC-related gene signature can be used for prognostication in HCC. Thus, targeting LPCs may serve as a therapeutic alternative for HCC.

Download Full-text